At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
New Yamuna Vihar facility to train 40 students annually through diploma-led, hands-on renal care education
The license is valid for five years, effective from April 9, 2026
Landmark procedure restores 32-year-old CKD patient’s health, highlighting how public insurance is widening access to advanced renal care
Surgeon Yuvaraja operates on a 55-year-old patient at Medical City Hospital Muscat
A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
Merck emphasized the broader significance of the findings
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
